USANA Health Sciences, Inc. (USNA, Financial) reported a notable increase in revenue for the first quarter, achieving $250 million compared to $228 million in the same period last year. This uptick reflects the company's successful execution of its growth strategy.
The firm attributes its strong performance to the continued momentum in its direct sales operations, complemented by its acquisition of Hiya, a direct-to-consumer business. This strategic addition has played a critical role in driving revenue growth.
USANA is experiencing a positive trend, witnessing modest sequential growth in both net sales and active customers over the past two quarters. This is seen as a promising indicator of the effectiveness of their current market approaches and customer engagement strategies.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Usana Health Sciences Inc (USNA, Financial) is $61.00 with a high estimate of $61.00 and a low estimate of $61.00. The average target implies an upside of 151.65% from the current price of $24.24. More detailed estimate data can be found on the Usana Health Sciences Inc (USNA) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Usana Health Sciences Inc's (USNA, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Usana Health Sciences Inc (USNA, Financial) in one year is $52.95, suggesting a upside of 118.44% from the current price of $24.24. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Usana Health Sciences Inc (USNA) Summary page.
